Testing QI-019B for hard-to-treat multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-stage trial tests a new drug called QI-019B in patients whose multiple myeloma (a blood cancer) has stopped responding to standard treatments. The study checks if QI-019B is safe and whether it helps slow or stop the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with multiple myeloma and have tried at least 2 different treatment regimens
- Your myeloma has gotten worse recently or within the last year, even with treatment
- Your blood tests show measurable amounts of myeloma protein
- You are healthy enough to tolerate the trial (good heart, liver, kidney, and lung function)
- You agree to use birth control for 1 year after the study drug and cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
This trial tests a new drug called SCTC21C combined with standard treatments (bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if this combination is safe and works better than current options.
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
This early-stage trial tests a new therapy called RN9101 for multiple myeloma that has come back or stopped responding to previous treatments. The drug targets a specific protein (BCMA) on myeloma cells and may help patients whose disease has progressed despite earlier therapies.
This trial tests a new drug called QLS4131 for people with multiple myeloma that has returned or not responded to treatment. It's a first-in-human study to see if the drug is safe and how well it works.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.